131926-98-2

131926-98-2 structure

Name: 5-Hydroxylansoprazole
Chemical Name: 5-hydroxy lansoprazole
CAS Number: 131926-98-2
Molecular Formula: C₁₆H₁₄F₃N₃O₃S
Molecular Weight: 385.36100
Catalog: Signaling Pathways Membrane Transporter/Ion Channel Proton Pump
Create Date: 2018-04-07 08:00:00
Modify Date: 2026-07-02 07:07:28
5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases[1][2].

Name	5-hydroxy lansoprazole
Synonyms	Lansoprazole Impurity 18 5'-hydroxylansoprazole 5-Hydroxy LansoprazoleQ: What is 5-Hydroxy Lansoprazole Q: What is the CAS Number of 5-Hydroxy Lansoprazole Q: What is the storage condition of 5-Hydroxy Lansoprazole Q: What e the applications of 5-Hydroxy Lansoprazole 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-5-ol Lansoprazole 5-Hydroxy 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-6-ol 5-Hydroxy Lansoprazole DISCONTINUED. See H943711 5-Hydroxy Lansoprazole 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-5-ol 2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole-5-ol 1H-Benzimidazol-6-ol, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl] 2-[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridylmethylsulfinyl]-5-hydroxy-1H-benzimidazole 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-3H-benzimidazol-5-ol 1-(1H-benzo[d]imidazol-2-yl)-2,3-dimethyl-4-(2,2,2- trifluoroethoxy)pyridin-1-ium AG-1908 Lansoprazole 5-Hydroxy Impurity

Description	5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases[1][2].
Related Catalog	Research Areas >> Metabolic Disease Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump
Target	Proton Pump[1]
References	[1]. Xu HR, et al. The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects. Pharm Biol. 2010 Aug;48(8):947-52. doi: 10.3109/13880200903300220. [2]. Katarína Kostolanská, et al. Determination of lansoprazole, 5-hydroxylansoprazole, and lansoprazole sulfone in human plasma for CYP2C19 and CYP3A4 phenotyping. Chemical Papers. volume 73, pages2955–2963(2019).